Treating smooth muscle hyperactivity with (R)-oxybutynin and (R)-desethyloxybutynin
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- WATSON PHARMA INC
- Publication Date
- 2003-11-05
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
technical field
[0001] The present invention relates to the optically active R(-)-isomer of 4-diethylamino-2-butynylcyclohexylphenyl glycolate and its name R(-)-4-ethylamino-2-butan Optically active metabolite of alkynylcyclohexylphenylglycolate. The compound 4-diethylamino-2-butynylcyclohexylphenyl glycolate, whose common name is oxybutynin (OXY), is an approved drug for the treatment of urinary incontinence and the treatment of gastrointestinal smooth muscle function Hyperactivity is also effective.
[0002] The oxybutynin (OXY) compound 4-ethylamino-2-butynylcyclohexylphenyl glycolate is known as desethyloxybutynin (DEO) and has the following chemical structure:
[0003] Desethyloxybutynin (DEO) Background technique
[0004] Racemic oxybutynin (OXY) is used therapeutically for the treatment of smooth muscle hyperactivity, such as urinary incontinence. OXY exerts its antispasmodic effect by inhibiting the ...